Tests intravenous ketamine for treatment-resistant depression in adults

Trial details

Who runs it

Mayo Clinic

Trial code

NCT06668571

Record updated

16 October 2026

Original description

The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.Read full original descriptionShow less

Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study

The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.

Inclusion: Ability to provide informed consent; Meets diagnostic criteria for major depressive disorder without psychotic features per the SCID DSM-IV-TR; PHQ-9 total score ≥ 15 at screening; Treatment-resistant depression, as defined by failure of at least two previous antidepressant treatments within the current depressive episode. Failed antidepressant treatments can include pharmacotherapy for depression at an adequate dose for at least 8 weeks, trial of transcranial magnetic stimulation (TMS) or an acute series of at least 6 administrations of electroconvulsive therapy (ECT); Ability to pass a comprehension assessment test related to effects of ketamine and trial objectives and criteria.

Exclusion: Medications known to affect glutamate (i.e., Riluzole, Carbamazepine) or GABA (zaleplon, zolpidem, zopiclone, Valproate, Gabapentin, Pregabalin, tiagabine, and vigabatrin) are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug; Monoamine Oxidase Inhibitors (MAOIs) are prohibited two weeks prior to administration of study drug; Opioid antagonists (naltrexone, naloxone, nalmefene, methylnaltrexone, buprenorphine and naloxone combination) are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug; CYP3A4 inducers carbamazepine and modafinil are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug; Use of methamphetamine, cocaine, or cannabis. Abuse of stimulant (s) within the prior 12 months; Clinical or self-reported diagnosis of delirium, encephalopathy, or related clinical diagnosis within the prior 12 months; Received ketamine treatment for depression within the prior 2 months; History of either poor antidepressive response to or poor tolerability of ketamine (any route of administration) when previously administered; Personality disorder being the primary diagnosis; Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or active psychotic symptoms; Active post-traumatic stress disorder symptoms based on clinical assessment; Any active or unstable medical condition judged by the study psychiatrist as conferring too great a level of medical risk to allow inclusion in the study; A history of bleeding in the brain; Arteriovenous malformation or a history of aneurysm; Any current substance use disorder (excluding nicotine and caffeine). Note: Persons will be allowed to enroll in this study if their substance use is in complete (not partial) and sustained (\> 1 year) remission; History of traumatic brain injury that resulted in loss of consciousness with brain bleeding; History of tonic-clonic (grand mal) seizures; Developmental delay, intellectual disability, or intellectual disorder; Minor or Major Neurocognitive disorder; History of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic for 3 months; Gastroesophageal reflux disease that is poorly managed; A diagnosis of Complex Regional Pain Syndrome (CRPS); History of claustrophobia with active symptoms that would interfere with the MRI; Poorly controlled hypertension; Hepatic insufficiency (2.5 X ULN for AST or ALT) within 3 months of consent, past liver transplant recipient, and/or clinical diagnosis of cirrhosis of the liver; Inability to speak English; Inability to provide consent or have a legal guardian; Patients with a BMI > 40 kg/m2; Ongoing prescription of > 2 mg lorazepam equivalents (total) daily, or morning dosing of any benzodiazepine at the time of assessment; Currently undergoing TMS, vagal nerve stimulation, or deep brain stimulation as either an acute or maintenance treatment of depression; ECT in the past 6 months; Pregnancy, or nursing; Any contraindication to MRI safety questionnaire.

ClinicalTrials.gov NCT06668571